Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial

NCT05995405 is registered in ClinicalTrials.gov with Grace Therapeutics Inc. as lead sponsor.

NCT NCT05995405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05995405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial
Lead sponsor
Grace Therapeutics Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 20, 2023
Completion date
December 31, 2024
Enrollment
100 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

aneurysmal subarachnoid hemorrhage (asah)